CEPTAZ
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1990
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CEPTAZ is an injectable small-molecule NDA approved by GSK in 1990, representing a mature product in its lifecycle with loss-of-exclusivity approaching. The specific indication and mechanism of action are not disclosed in available data, but the injectable route suggests acute or chronic condition treatment. This product is in the small-molecule category and has been on the market for over three decades.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%) suggests declining team headcount and transition focus toward pipeline or newer assets within GSK's portfolio.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for CEPTAZ-specific roles at this time. Career development on this product is limited due to LOE approaching; professionals should expect defensive strategies focused on market share retention rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on CEPTAZ at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.